Analysis of conditioning with dexmedetomidine under endothelial dysfunction in isolated perfused hearts

De Luca-rohner,Sophia; Heinen,André; Stroethoff,Martin; Raupach,Annika

doi:10.3892/br.2025.2014

Analysis of conditioning with dexmedetomidine under endothelial dysfunction in isolated perfused hearts

Authors:
- Sophia De Luca-rohner
- André Heinen
- Martin Stroethoff
- Annika Raupach
View Affiliations

Affiliations: Department of Anaesthesiology, Medical Faculty and University Hospital Düsseldorf, Heinrich‑Heine‑University Düsseldorf, Düsseldorf D-40225, Germany, Institute for Cardiovascular Physiology, Medical Faculty and University Hospital Düsseldorf, Heinrich‑Heine University Düsseldorf, Düsseldorf D-40225, Germany
Published online on: June 11, 2025 https://doi.org/10.3892/br.2025.2014
Article Number: 136
Copyright : © De Luca-rohner et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardioprotective strategies such as pharmacological conditioning have not yet successfully undergone bench‑to‑bedside transfer, which is probably due to inhibition of cardioprotection by comorbidities or associated pathological changes. Endothelial dysfunction (ED) is closely associated with most cardiovascular diseases and their typical comorbidities. Therefore, cardioprotective strategies should be examined under ED. It was previously demonstrated that dexmedetomidine (DEX) maintains its cardioprotective properties against ischemia/reperfusion (I/R) injury under hyperglycaemia in the setting of pre‑but not postconditioning, using a constant pressure Langendorff system. Under ED, cardioprotection by DEX preconditioning is also maintained using a constant flow mode, whereas this has not yet been investigated for postconditioning. Because DEX has vasoconstrictive properties, different haemodynamic conditions might influence the cardioprotective potential of DEX. Therefore, it was investigated whether pre‑ and postconditioning protocols with DEX used in constant pressure mode are transferable to constant flow mode and whether the cardioprotective effect of DEX is maintained under ED. The cardioprotective effect against I/R injury of pre‑ and post‑treatment with 3 nM DEX on isolated‑perfused hearts of male Wistar rats was analysed in constant flow mode. ED was induced by perfusion with Krebs‑Henseleit buffer containing 60 mM KCl. Heart function was assessed via pressure measurements in the left ventricle (LV) and infarct size (IS) via triphenyltetrazolium‑chloride staining. In constant flow mode, pre‑ and post‑treatment with DEX has no effect on IS and heart function compared with hearts treated with vehicle both under ED and under physiological conditions. In DEX pre‑treated hearts under ED, LV developed pressure is increased and contractility is improved after 60 min of reperfusion. Pre‑ and post‑treatment with DEX is not cardioprotective with the protocol used, while DEX pre‑treatment under ED has improving effects on heart function. Different hemodynamic conditions may modulate the cardioprotective properties of DEX, possibly due to its vasoconstrictive properties.

View Figures

View References

1	Heusch G: Cardioprotection and its translation: A need for new paradigms? Or for new pragmatism? An opinionated retro- and perspective. J Cardiovasc Pharmacol Ther. 28(10742484231179613)2023.PubMed/NCBI View Article : Google Scholar
2	Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al: Heart disease and stroke statistics-2020 update: A report from the American heart association. Circulation. 141:e139–e596. 2020.PubMed/NCBI View Article : Google Scholar
3	Kleinbongard P, Botker HE, Ovize M, Hausenloy DJ and Heusch G: Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? Br J Pharmacol. 177:5252–5269. 2020.PubMed/NCBI View Article : Google Scholar
4	Segers VFM, Bringmans T and De Keulenaer GW: Endothelial dysfunction at the cellular level in three dimensions: Severity, acuteness, and distribution. Am J Physiol Heart Circ Physiol. 325:H398–H413. 2023.PubMed/NCBI View Article : Google Scholar
5	Roy R, Wilcox J, Webb AJ and O'Gallagher K: Dysfunctional and dysregulated nitric oxide synthases in cardiovascular disease: Mechanisms and therapeutic potential. Int J Mol Sci. 24(15200)2023.PubMed/NCBI View Article : Google Scholar
6	Cyr AR, Huckaby LV, Shiva SS and Zuckerbraun BS: Nitric oxide and endothelial dysfunction. Crit Care Clin. 36:307–321. 2020.PubMed/NCBI View Article : Google Scholar
7	Behmenburg F, Pickert E, Mathes A, Heinen A, Hollmann MW, Huhn R and Berger MM: The cardioprotective effect of dexmedetomidine in rats is dose-dependent and mediated by BKCa channels. J Cardiovasc Pharmacol. 69:228–235. 2017.PubMed/NCBI View Article : Google Scholar
8	Bunte S, Behmenburg F, Majewski N, Stroethoff M, Raupach A, Mathes A, Heinen A, Hollmann MW and Huhn R: Characteristics of dexmedetomidine postconditioning in the field of myocardial ischemia-reperfusion injury. Anesth Analg. 130:90–98. 2020.PubMed/NCBI View Article : Google Scholar
9	He L, Hao S, Wang Y, Yang W, Liu L, Chen H and Qian J: Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction. Biomed Pharmacother. 114(108837)2019.PubMed/NCBI View Article : Google Scholar
10	Torregroza C, Feige K, Schneider L, Bunte S, Stroethoff M, Heinen A, Hollmann MW, Huhn R and Raupach A: Influence of hyperglycemia on dexmedetomidine-induced cardioprotection in the isolated perfused rat heart. J Clin Med. 9(1445)2020.PubMed/NCBI View Article : Google Scholar
11	Castillo RL, Ibacache M, Cortinez I, Carrasco-Pozo C, Farías JG, Carrasco RA, Vargas-Errázuriz P, Ramos D, Benavente R, Torres DH and Méndez A: Dexmedetomidine Improves Cardiovascular and ventilatory outcomes in critically Ill patients: Basic and clinical approaches. Front Pharmacol. 10(1641)2019.PubMed/NCBI View Article : Google Scholar
12	Skrzypiec-Spring M, Grotthus B, Szelag A and Schulz R: Isolated heart perfusion according to Langendorff-still viable in the new millennium. J Pharmacol Toxicol Methods. 55:113–126. 2007.PubMed/NCBI View Article : Google Scholar
13	Cartier R, Pellerin M, Hollmann C and Pelletier LC: Effects of pressure and duration of hyperkalemic infusions on endothelial function. Ann Thorac Surg. 55:700–705. 1993.PubMed/NCBI View Article : Google Scholar
14	Raupach A, Karakurt E, Torregroza C, Bunte S, Feige K, Stroethoff M, Brandenburger T, Heinen A, Hollmann MW and Huhn R: Dexmedetomidine provides cardioprotection during early or late reperfusion mediated by different mitochondrial K+-channels. Anesth Analg. 132:253–260. 2021.PubMed/NCBI View Article : Google Scholar
15	Faul F, Erdfelder E, Lang AG and Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39:175–191. 2007.PubMed/NCBI View Article : Google Scholar
16	Wang L, Liu J, Wang Z, Qian X, Zhao Y, Wang Q, Dai N, Xie Y, Zeng W, Yang W, et al: Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis. Biomed Pharmacother. 165(115255)2023.PubMed/NCBI View Article : Google Scholar
17	Okada H, Kurita T, Mochizuki T, Morita K and Sato S: The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation. 74:538–545. 2007.PubMed/NCBI View Article : Google Scholar
18	Takahashi K, Yoshikawa Y, Kanda M, Hirata N and Yamakage M: Dexmedetomidine as a cardioprotective drug: A narrative review. J Anesth. 37:961–970. 2023.PubMed/NCBI View Article : Google Scholar
19	Yoshikawa Y, Hirata N, Kawaguchi R, Tokinaga Y and Yamakage M: Dexmedetomidine maintains its direct cardioprotective effect against ischemia/reperfusion injury in hypertensive hypertrophied myocardium. Anesth Analg. 126:443–452. 2018.PubMed/NCBI View Article : Google Scholar
20	Mimuro S, Katoh T, Suzuki A, Yu S, Adachi YU, Uraoka M, Sano H and Sato S: Deterioration of myocardial injury due to dexmedetomidine administration after myocardial ischaemia. Resuscitation. 81:1714–1717. 2010.PubMed/NCBI View Article : Google Scholar
21	Riquelme JA, Westermeier F, Hall AR, Vicencio JM, Pedrozo Z, Ibacache M, Fuenzalida B, Sobrevia L, Davidson SM, Yellon DM, et al: Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism. Pharmacol Res. 103:318–327. 2016.PubMed/NCBI View Article : Google Scholar
22	Ghasemi A and Jeddi S: Quantitative aspects of nitric oxide production in the heart. Mol Biol Rep. 49:11113–11122. 2022.PubMed/NCBI View Article : Google Scholar
23	Ibacache M, Sanchez G, Pedrozo Z, Galvez F, Humeres C, Echevarria G, Duaso J, Hassi M, Garcia L, Díaz-Araya G and Lavandero S: Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart. Biochim Biophys Acta. 1822:537–545. 2012.PubMed/NCBI View Article : Google Scholar
24	Trejo-Moreno C, Jimenez-Ferrer E, Castro-Martinez G, Méndez-Martínez M, Santana MA, Arrellín-Rosas G, Pedraza-Chaverri J, Medina-Campos ON, Hernández-Téllez B, Ramírez-Pliego O, et al: Characterization of a murine model of endothelial dysfunction induced by chronic intraperitoneal administration of angiotensin II. Sci Rep. 11(21193)2021.PubMed/NCBI View Article : Google Scholar
25	Khaliulin I, Clarke SJ, Lin H, Parker J, Suleiman MS and Halestrap AP: Temperature preconditioning of isolated rat hearts-a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol. 581:1147–1161. 2007.PubMed/NCBI View Article : Google Scholar
26	Querio G, Geddo F, Antoniotti S, Gallo MP and Penna C: Sex and response to cardioprotective conditioning maneuvers. Front Physiol. 12(667961)2021.PubMed/NCBI View Article : Google Scholar
27	Vincent KF, Mallari OG, Dillon EJ, Stewart VG, Cho AJ, Dong Y, Edlow AG, Ichinose F, Xie Z and Solt K: Oestrous cycle affects emergence from anaesthesia with dexmedetomidine, but not propofol, isoflurane, or sevoflurane, in female rats. Br J Anaesth. 131:67–78. 2023.PubMed/NCBI View Article : Google Scholar
28	Ding Y, Liu A, Wang Y, Zhao S, Huang S, Zhu H, Ma L, Han L, Shu S, Zheng L and Chen X: Genetic polymorphisms are associated with individual susceptibility to dexmedetomidine. Front Genet. 14(1187415)2023.PubMed/NCBI View Article : Google Scholar